Agape ATP Corp(ATPC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ATPC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Agape ATP Corp (ATPC), a Healthcare sector company. ATPC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Agape ATP Corp reports quarterly revenue of $273.7K, net income of $-340.9K, free cash flow of $-394.8K. ATPC trades on the Nasdaq exchange and files with the SEC under CIK 1713210. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATPC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Agape ATP Corp directly from SEC EDGAR.
Revenue
Q1 2026
$273.7K
Net Income
Q1 2026
$-340.9K
Free Cash Flow
Q1 2026
$-394.8K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+15.2% YoYNet Income
+7.7% YoYOperating Income
-26.6% YoYEPS (Diluted)
+91.0% YoYTotal Assets
+659.0% YoYOp. Cash Flow
+11.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $1.5M +15.2% | $1.3M -7.6% | $1.4M -22.9% | $1.9M +82.6% | $1.0M -21.2% | $1.3M |
| Net Income | $-2.3M +7.7% | $-2.5M -17.5% | $-2.1M -24.6% | $-1.7M +33.2% | $-2.5M -252.5% | $-716.1K |
| Operating Income | $-3.3M -26.6% | $-2.6M -19.9% | $-2.1M -40.0% | $-1.5M +17.5% | $-1.9M -490.8% | $-314.6K |
| EPS (Diluted) | $-2.85 +91.0% | $-31.74 -5670.9% | $-0.55 -2650.0% | $-0.02 | — | — |
| Total Assets | $24.6M +659.0% | $3.2M -43.6% | $5.7M +105.8% | $2.8M -40.9% | $4.7M +9.0% | $4.3M |
| Operating Cash Flow | $-2.4M +11.5% | $-2.7M -36.2% | $-2.0M -146.6% | $-811.7K +4.0% | $-845.8K -20.1% | $-704.4K |
AI Insight: ATPC Financial Trends
Pre-revenue biotech burning cash at ~$1M quarterly with equity cushion eroding despite Q1 2025 capital raise.
• Operating losses stabilized at ~$1M per quarter Q3 2024–Q1 2026; no revenue generation across entire period.
• Equity jumped from $2M (Q4 2024) to $24M (Q1 2025), indicating ~$22M financing event; erosion to $22M by Q1 2026.
• Operating cash flow remained near-flat negative ($0–$1M) throughout, with no debt outstanding across all periods.
⚠ Equity base of $22M at Q1 2026 funding runway ~22 quarters at current $1M quarterly burn; no clear inflection visible.
⚠ Zero revenue and no operating improvement across 9 quarters suggest clinical/commercial development remains early-stage.
AI Insight: ATPC Ratio Trends
Agape ATP remains deeply unprofitable across all profitability metrics, though ROE/ROA show modest stabilization near -6% in latest quarter after severe deterioration in 2024.
• ROE improved from -167.3% in Q4 2024 to -6.2% in Q1 2026, signaling a structural shift away from extreme losses.
• Net profit margin remains severely negative at -124.6% in Q1 2026, reflecting ongoing operational cash burn.
• ROIC stabilized around -10% to -12% in Q2–Q3 2025 before widening to -12.2% in Q1 2026.
⚠ Operating margin data gaps in Q4 2024, Q1 2025, and Q4 2025 limit visibility into cost control progress.
⚠ ROIC deteriorated from -10.5% in Q3 2025 to -23.1% in Q4 2025—first major weakness after stabilization.
Get alerted when ATPC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Agape ATP Corp including:
Top Institutional Holders of ATPC
JANE STREET GROUP, LLC
$62.2K23,660 shUBS Group AG
$6.8K2,590 sh
| Fund | Value | Shares |
|---|---|---|
| JANE STREET GROUP, LLC | $62.2K | 23,660 |
| UBS Group AG | $6.8K | 2,590 |
More Healthcare Companies
View all Healthcare →Put ATPC on your watchlist
Track score changes the day Agape ATP Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ATPC a good stock to buy?
13F Pro's AI-powered analysis of Agape ATP Corp (ATPC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATPC are available on the ATPC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ATPC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATPC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Agape ATP Corp's investment landscape.